+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Years - 17Years
All Genders
ID06979453

Evaluating Deucravacitinibs Efficacy, Safety, and Drug Levels in Adolescents with Moderate to Severe Plaque Psoriasis Using a Randomized, Double-Blind, Placebo-Controlled Design

Led by Bristol-Myers Squibb · Updated on 2026-10-27

366

Participants Needed

133

Research Sites

252 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the effects of Deucravacitinib BMS-986165 in adolescents aged 12 to 17 years with moderate to severe plaque psoriasis. The study aims to assess the drugs effectiveness, safety, and how it behaves in the body. This phase 3 trial is designed as a randomized, double-blind, placebo-controlled investigation to provide clear evidence of the drugs impact in this younger population. Participants are randomly assigned to receive either Deucravacitinib or a placebo following specified dosing schedules. The study involves a parallel group design where the treatment is given on specified days. The trial will monitor participants closely over time to evaluate treatment responses and any side effects, especially focusing on improvements in psoriasis severity and skin condition. During the study, participants will have regular assessments including measurement of psoriasis severity by Psoriasis Area and Severity Index PASI and Physicians Global Assessment sPGA, body surface area affected, itch severity, and quality of life. Safety monitoring includes checking for adverse events, laboratory tests, physical exams, vital signs, and vaccine antibody levels. The study also tracks growth and sexual maturation over up to five years, providing long-term data on drug safety and participant health.

CONDITIONS

Brief Title

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Research Team

B

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

F

First line of the email MUST contain NCT # and Site #.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here